220 related articles for article (PubMed ID: 16232025)
1. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting.
Zarowitz BJ; Stebelsky LA; Muma BK; Romain TM; Peterson EL
Pharmacotherapy; 2005 Nov; 25(11):1636-45. PubMed ID: 16232025
[TBL] [Abstract][Full Text] [Related]
2. Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews.
Fillit HM; Futterman R; Orland BI; Chim T; Susnow L; Picariello GP; Scheye EC; Spoeri RK; Roglieri JL; Warburton SW
Am J Manag Care; 1999 May; 5(5):587-94. PubMed ID: 10537865
[TBL] [Abstract][Full Text] [Related]
3. Effects of a polypharmacy edit and reduced quantity limits on the utilization of triptans and overall costs in an integrated health system.
Dunn JD; Cannon HE
Manag Care Interface; 2006 May; 19(5):46-51. PubMed ID: 16786970
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the North Carolina long-term care polypharmacy initiative: a multiple-cohort approach using propensity-score matching for both evaluation and targeting.
Trygstad TK; Christensen DB; Wegner SE; Sullivan R; Garmise JM
Clin Ther; 2009 Sep; 31(9):2018-37. PubMed ID: 19843492
[TBL] [Abstract][Full Text] [Related]
5. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data.
Solberg LI; Hurley JS; Roberts MH; Nelson WW; Frost FJ; Crain AL; Gunter MJ; Young LR
Am J Manag Care; 2004 Nov; 10(11 Pt 1):753-9. PubMed ID: 15623265
[TBL] [Abstract][Full Text] [Related]
6. Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions.
Tulner LR; Kuper IM; Frankfort SV; van Campen JP; Koks CH; Brandjes DP; Beijnen JH
Am J Geriatr Pharmacother; 2009 Apr; 7(2):93-104. PubMed ID: 19447362
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
8. Costs of care for HIV infection in a managed care population from 1995 to 1997.
Lapins DL; Urdaneta ME; Barrett J; Hamel EC; Duong PT; Markson LE
Am J Manag Care; 2000 Sep; 6(9):973-81. PubMed ID: 11184068
[TBL] [Abstract][Full Text] [Related]
9. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people.
Garfinkel D; Zur-Gil S; Ben-Israel J
Isr Med Assoc J; 2007 Jun; 9(6):430-4. PubMed ID: 17642388
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
11. Mitigation of medication mishaps via medication therapy management.
Pindolia VK; Stebelsky L; Romain TM; Luoma L; Nowak SN; Gillanders F
Ann Pharmacother; 2009 Apr; 43(4):611-20. PubMed ID: 19336646
[TBL] [Abstract][Full Text] [Related]
12. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management.
Sokol KC; Knudsen JF; Li MM
J Clin Pharm Ther; 2007 Apr; 32(2):169-75. PubMed ID: 17381667
[TBL] [Abstract][Full Text] [Related]
13. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
14. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
[TBL] [Abstract][Full Text] [Related]
15. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting.
Craig DS
Pharmacotherapy; 2006 Jun; 26(6):886-7; discussion 887. PubMed ID: 16716143
[No Abstract] [Full Text] [Related]
16. Effect of a retrospective drug utilization review on potentially inappropriate prescribing in the elderly.
Starner CI; Norman SA; Reynolds RG; Gleason PP
Am J Geriatr Pharmacother; 2009 Feb; 7(1):11-9. PubMed ID: 19281936
[TBL] [Abstract][Full Text] [Related]
17. Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners.
Roughead E; Pratt N; Peck R; Gilbert A
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):797-803. PubMed ID: 17476702
[TBL] [Abstract][Full Text] [Related]
18. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
19. High-risk population health management--achieving improved patient outcomes and near-term financial results.
Lynch JP; Forman SA; Graff S; Gunby MC
Am J Manag Care; 2000 Jul; 6(7):781-91. PubMed ID: 11067375
[TBL] [Abstract][Full Text] [Related]
20. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
